Related Experiment Video
Updated: May 23, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?
Daniel C Cho1, Michael B Atkins
1Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. dcho1@bidmc.harvard.edu
Abstract:
Lee and colleagues report that increase in serum cholesterol is associated with improved clinical outcomes in patients with renal cell carcinoma treated with temsirolimus. Although these findings must be validated prospectively, it should also be determined if this marker is a true mechanism-based toxicity or an epiphenomenon associated with therapy.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cholesterol: Significance and Regulation
Considering cholesterol and...
PI3K/mTOR/AKT Signaling Pathway
Pharmacogenomics: Identification of New Drug Targets
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
